JAK2 and myeloproliferative disorder: Hence any model for activation must remove the PK domain away from the kinase domain, and it is notable that myeloproliferative neoplasms with constitutive JAK2 activation possess point mutations in the PK domain or the linker to the adjacent SH2 domain, rather than the kinase domain.